Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

Luca Mastorino; Niccolò Siliquini; Gianluca Avallone; Michela Ortoncelli; Pietro Quaglino; Paolo Dapavo; Simone Ribero

doi:10.4081/dr.2022.9282

Authors

Luca Mastorino
lucamastorino02@gmail.com
Medical Science Department, Section of Dermatology, University of Turin, Italy. https://orcid.org/0000-0001-7386-3219
Niccolò Siliquini Medical Science Department, Section of Dermatology, University of Turin, Italy.
Gianluca Avallone Medical Science Department, Section of Dermatology, University of Turin, Italy. https://orcid.org/0000-0001-7253-2370
Michela Ortoncelli Medical Science Department, Section of Dermatology, University of Turin, Italy.
Pietro Quaglino Medical Science Department, Section of Dermatology, University of Turin, Italy.
Paolo Dapavo University of Turin, Department of Medical Sciences, Italy.
Simone Ribero Medical Science Department, Section of Dermatology, University of Turin, Italy.

To the Editor:
Limited evidence on the use of biologic treatments in psoriatic patients with a history of malignancy is currently available in the literature. The recently published European guidelines recommend the use of anti-TNF, anti-IL17, and anti-23 biological drugs in this special population after discussion case-by-case with a cancer-specialist [...].

Nast A, Smith C, Spuls PI et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021;35:281-317. DOI: https://doi.org/10.1111/jdv.16926

Kahn JS, Casseres RG, Her MJ. Treatment of psoriasis with biologics and Apremilast in patients with a history of malignancy: a retrospective chart review. J Drugs Dermatol 2019;18.

Bellinato F, Gisondi P, Maurelli M, Girolomoni G. IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review. Dermatol Ther 2021;34:e14889. DOI: https://doi.org/10.1111/dth.14889

Chyuan IT, Lai JH. New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochem Pharmacol 2020;175:113928. DOI: https://doi.org/10.1016/j.bcp.2020.113928

Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017;76:418-31. DOI: https://doi.org/10.1016/j.jaad.2016.11.042

Bilal J, Berlinberg A, Bhattacharjee, et al. A systematic review and meta- analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat 2018;29:569-78. DOI: https://doi.org/10.1080/09546634.2017.1422591

Kamiya K, Yamauchi H, Ohtsuki M. Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer. Eur J Dermatol 2020;30:609-11. DOI: https://doi.org/10.1684/ejd.2020.3860

Mastorino, L., Siliquini, N., Avallone, G., Ortoncelli, M., Quaglino, P., Dapavo, P., & Ribero, S. (2022). Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis. Dermatology Reports, 14(3). https://doi.org/10.4081/dr.2022.9282